Novartis AG Common Stock (NVS)

The company is focused on treatments for forms of muscular dystrophy.

In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the pharmaceutical giant and the wider healthcare industry, which has been navigating a complex landscape of regulatory scrutiny, patent expirations,

US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may not happen soon.

The United States current-account deficit expanded sharply to $450 billion in the first half of 2025, marking a renewed widening of the country's financial shortfall with the rest of the world. This expansion reflects a persistent imbalance between what the nation imports and what it exports in goods, services, income,

Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients.

NOVARTIS AG (NVS) is a top dividend stock with a 3.76% yield, strong profitability, and financial stability, making it ideal for income-focused investors.

Sarepta stock is now trading at a nine-year low as the debacle with its gene therapy, Elevidys, continues.

AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.

At the center of the company’s plan is a new, multi-billion-dollar manufacturing facility in Virginia.

NOVARTIS AG (NYSE:NVS) presents a value opportunity with strong profitability, financial health, and reasonable growth, trading below industry and market valuations.

The company's second biggest product missed sales expectations. Shares look likely to undercut a buy zone.

Novartis posts solid Q2 results, raises 2025 earnings outlook, launches $10 billion share buyback, and announces CFO succession plan amid strong drug sales.

Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.

The stock slid to an intraday low of ₹6,545 on Monday following a gap-down open, as investors reacted to MSN’s legal win over Entresto.

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety concerns reported.

Novartis' Coartem Baby wins Swiss approval as the first malaria drug for newborns under 5 kg, offering safer dosing and easier administration.